Skip to content
value.today

Design Therapeutics, Inc.

🇺🇸 Solana Beach, California, USAPharmaceuticalsFounded 2017
Total raised
$171 M
2 rounds on record
Latest round
$125 M
Jan 2021
First round on record
Feb 2020
Today
Went public
See the company page

Design Therapeutics, Inc. is listed today as Design Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Design Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2021$125 MNo. 2$50 to $250 million

Design Therapeutics, Inc.: Raise no. 2, Jan 2021

Investors in this round

26 investors had bought by the notice of Feb 12, 2021: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Design Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$125 M of $125 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joao Siffert, M.D. · Executive Officer, Director
  • Pratik Shah, Ph.D. · Executive Officer, Director
  • Sean Jeffries, Ph.D. · Executive Officer
  • Arsani William, M.D. · Director
  • John Schmid · Director
  • Rodney Lappe, Ph.D. · Director
  • Simeon George, M.D. · Director
  • Stella Xu, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joao Siffert, M.D., President and CEO. Source: SEC Form D, newest notice filed Feb 12, 2021. Read the notice at the SEC.

equitySEC
Feb 2020$46 MNo. 1$10 to $50 million

Design Therapeutics, Inc.: Raise no. 1, Feb 2020

Investors in this round

6 investors had bought by the notice of Jun 3, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Design Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$46 M of $46 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Pratik Shah, Ph.D. · Executive Officer, Director
  • Sean Z. Jeffries, Ph.D. · Executive Officer
  • Aseem Z. Ansari, Ph.D. · Director
  • Rodney Z. Lappe, Ph.D. · Director
  • Simeon Z. George, M.D. · Director
  • Stella Z. Xu, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean Jeffries, Ph.D., Chief Business Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 3, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Design Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2021

That is all the official record says: Design Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Design Therapeutics, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Design Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund II, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Quan Venture Fund II, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
SR One Capital Fund I Aggregator LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
SR One Capital Management, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
SR One Capital Partners I, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 26 investors.

Largest shareholders today

Institutions holding Design Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Design Therapeutics, Inc.
NameRoleNamed in
Joao Siffert, M.D.Executive officerFeb 2021
Pratik Shah, Ph.D.Executive officerFeb 2021
Sean Jeffries, Ph.D.Executive officerFeb 2021
Sean Z. Jeffries, Ph.D.Executive officerJun 2020
Arsani William, M.D.DirectorFeb 2021
Joao Siffert, M.D.DirectorFeb 2021
John SchmidDirectorFeb 2021
Pratik Shah, Ph.D.DirectorFeb 2021
Rodney Lappe, Ph.D.DirectorFeb 2021
Simeon George, M.D.DirectorFeb 2021
Stella Xu, Ph.D.DirectorFeb 2021
Aseem Z. Ansari, Ph.D.DirectorJun 2020
Rodney Z. Lappe, Ph.D.DirectorJun 2020
Simeon Z. George, M.D.DirectorJun 2020
Stella Z. Xu, Ph.D.DirectorJun 2020

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.